Updated:
Ferring Pharmaceuticals
Ferring Pharmaceuticals is a biopharmaceutical group founded in 1950 in Saint-Prex, Switzerland. The company specializes in reproductive medicine, maternal...
Ferring Pharmaceuticals
Ferring Pharmaceuticals is a biopharmaceutical group founded in 1950 in Saint-Prex, Switzerland. The company specializes in reproductive medicine, maternal health, gastroenterology, and urology. It was previously known as Nordiska Hormon Laboratoriet.
General information
Firm type
Asset Manager
Location
Region
Europe
Country
Switzerland
City
Saint-Prex
Corporate office
Ch. de la Vergognausaz 50, 1162 Saint-Prex, Switzerland
Sector focus
Frequently asked questions
Does Ferring deploy capital into external funds or direct investments?
No. Ferring does not make external venture capital investments, private equity allocations or LP commitments. Its deployment is entirely internal, focused on drug development, clinical trials and global commercialization infrastructure.
What is Ferring’s flagship product and what drives its revenue growth?
Menopur, a reproductive medicine treatment, is the historical flagship and primary revenue driver. The firm’s second growth leg is Adstiladrin, a gene therapy for high-risk bladder cancer, which began a commercial ramp in the US market and contributed to 10 percent revenue growth in 2025.
What is Ferring’s geographic investment footprint?
Ferring operates in more than 50 countries. Its commercial activity is global, with meaningful presence in North America, Europe and Asia Pacific. In April 2026, it launched a global fertility study in partnership with Gallup to collect data from 70 countries.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: